Gemini Scientists

Pipeline

Our research pipeline is designed to develop treatments for genetically defined subpopulations of patients suffering from dry AMD and linked diseases. This could provide patients with access to targeted first-in-class medicines for patients with limited therapeutic options.

Ocular Disease Platform

Age-Related Macular Degeneration

Target
Research
Preclinical
Clinical
CLARITY 1

Status: Clinical


CLARITY 2

Status: Clinical


Precision Medicine Pipeline

Age-Related Macular Degeneration

Target
Research
Preclinical
Clinical
GEM103

Modality: Recombinant Protein

Status: Clinical


AAV-CFH

Modality: Gene Therapy

Gene Therapy Icon

Status: Preclinical


Complement Factor I

GEM104

Modality: Recombinant Protein

Status: Preclinical


AAV-CFI

Modality: Gene Therapy

Gene Therapy Icon

Status: Preclinical


Ocular Disease

Target
Research
Preclinical
Clinical

HTRA1

mAb

Modality: Monoclonal Antibody

Status: Research


AAV-Ab

Modality: Gene Therapy

Gene Therapy Icon

Status: Research


Systemic Renal

Target
Modality
Research
Preclinical
Clinical

CFH Agonistic Antibody

GEM307

Modality: Monoclonal Antibody

Status: Preclinical